Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

ConditionMalaria Vaccine

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age3-59

SponsorEpicentre

About this trial

This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the eﬀectiveness and real-life impact of a novel integrated delivery strategy of the R21 malaria vaccine alongside SMC among children in areas with highly seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a health centre. Clusters will be randomised to receive either year-round age-based routine EPI vaccination for children aged 5-36 months ("Routine EPI Vaccination") in Burkina Faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and SMC delivery (''Routine Pre-SMC vaccination'') in Mali versus an annual campaign of the 3-dose primary series aligned with SMC distribution in children aged 3-59 months ("Integrated SMC Vaccination") in each country. Eﬀectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-eﬀectiveness.

Malaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. Cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. In addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of R21/Matrix-M will be assessed.

Eligibility criteria

Qualifiers

Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination;

Resident in the catchment area of a health centre assigned to the control arm;

Willingness to comply with the study procedures;

Written informed consent from Parent/Guardian.

Disqualifiers

History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines;

Any history of anaphylaxis in relation to vaccination;

Known chronic illness;

Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial;

Trial design

Treatments tested in this trial

Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months

Treatment groups

40,000 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Epicentre

Lead sponsor

R-Evolution Worldwide

Collaborator

CNRST Burkina Faso

Collaborator

USTTB Mali

Collaborator

Liverpool School of Tropical Medicine

Collaborator

Source ClinicalTrials.gov